Literature DB >> 15840634

The impact of China's retail drug price control policy on hospital expenditures: a case study in two Shandong hospitals.

Qingyue Meng1, Gang Cheng, Lynn Silver, Xiaojie Sun, Clas Rehnberg, Göran Tomson.   

Abstract

In China, 44.4% of total health expenditures in 2001 were for pharmaceuticals. Containment of pharmaceutical expenditures is a top priority for policy intervention. Control of drug retail prices was adopted by the Chinese government for this purpose. This study aims to examine the impact of this policy on the containment of hospital drug expenditures, and to analyze contributing factors. This is a retrospective pre/post-reform case study in two public hospitals. Financial records were reviewed to analyze changes in drug expenditures for all patients. A tracer condition, cerebral infarction, was selected for in-depth examination of changes in prices, utilization, expenditures and rationality of drugs. In the two hospitals, a total of 104 and 109 cerebral infarction cases, hospitalized respectively before and after the reform, were selected. Prescribed daily dose (PDD) was used for measuring drug utilization, and the contribution of price and utilization to changes in drug expenditures were decomposed. Rationality of drug use post-reform was reviewed based on published literature. Drug expenditures for all patients still increased rapidly in the two hospitals after implementation of the pricing policy. In the provincial hospital, drug expenditures per patient for cerebral infarction cases declined, but not significantly. This was mainly attributable to reduced utilization. In the municipal hospital, drug expenditure per patient increased by 50.1% after the reform, mainly due to greater drug utilization. Three to five fold higher drug expenditure per inpatient day in the provincial hospital was due to use of more expensive drugs. Of the top 15 drugs for treating cerebral infarction cases after the reform, 19.5% and 46.5% of the expenditures, in the provincial and municipal hospitals, respectively, were spent on drugs with prices set by the government. A large proportion of expenditures for the top 15 drugs, at least 65% and 41% in the provincial and municipal hospitals, respectively, was spent on allopathic drugs without an adequate evidence base of safety and efficacy supporting use for cerebral infarction. Control of retail prices, implemented in isolation, was not effective in containing hospital drug expenditures in these two Chinese hospitals. Utilization, more than price, determined drug expenditures. Improvement of rational use of drugs and correcting the present incentive structure for hospitals and drug prescribers may be important additional strategies for achieving containment of drug expenditures.

Entities:  

Mesh:

Year:  2005        PMID: 15840634     DOI: 10.1093/heapol/czi018

Source DB:  PubMed          Journal:  Health Policy Plan        ISSN: 0268-1080            Impact factor:   3.344


  18 in total

1.  Time trends and determinants of pharmaceutical expenditure in China (1990-2009).

Authors:  Lizheng Shi; Heidi Y Yang; Gang Cheng; Qingyue Meng
Journal:  Pharmacoeconomics       Date:  2014-03       Impact factor: 4.981

2.  Impact of anticancer drugs price cut on physician's prescription choices on first-line chemotherapy regimens and health expenditure for advanced non-small cell lung cancer in China.

Authors:  Bei Li; Mei-Ying Li; Luan-Luan Sun; Jian Wang; Yan-Qing Zheng; Jing Hao
Journal:  J Thorac Dis       Date:  2016-10       Impact factor: 2.895

3.  Availability and use of essential medicines in China: manufacturing, supply, and prescribing in Shandong and Gansu provinces.

Authors:  Wen Chen; Shenglan Tang; Jing Sun; Dennis Ross-Degnan; Anita K Wagner
Journal:  BMC Health Serv Res       Date:  2010-07-17       Impact factor: 2.655

4.  The political economy of healthcare reform in China: negotiating public and private.

Authors:  Arthur Daemmrich
Journal:  Springerplus       Date:  2013-09-10

5.  Influence of Government Price Regulation on the Price, Volume and Spending of Antibiotics in China: A Controlled Interrupted Time Series Study.

Authors:  Haishaerjiang Wushouer; Zhenhuan Luo; Xiaodong Guan; Luwen Shi
Journal:  Int J Health Policy Manag       Date:  2022-02-01

6.  Uptake of new antidiabetic medications in three emerging markets: a comparison between Brazil, China and Thailand.

Authors:  Christine Y Lu; Isabel Cristina M Emmerick; Peter Stephens; Dennis Ross-Degnan; Anita K Wagner
Journal:  J Pharm Policy Pract       Date:  2015-02-16

7.  Prescribing efficiency of proton pump inhibitors in China: influence and future directions.

Authors:  Wenjie Zeng; Alexander E Finlayson; Sushma Shankar; Winnie de Bruyn; Brian Godman
Journal:  BMC Health Serv Res       Date:  2015-01-22       Impact factor: 2.655

8.  Effects of drug price reduction and prescribing restrictions on expenditures and utilisation of antihypertensive drugs in Korea.

Authors:  Ki-Bong Yoo; Sang Gyu Lee; Sohee Park; Tae Hyun Kim; Jeonghoon Ahn; Mee-Hyun Cho; Eun-Cheol Park
Journal:  BMJ Open       Date:  2015-07-15       Impact factor: 2.692

9.  The effect of the National Essential Medicines Policy on health expenditures and service delivery in Chinese township health centres: evidence from a longitudinal study.

Authors:  Xin Zhang; Qunhong Wu; Guoxiang Liu; Ye Li; Lijun Gao; Bin Guo; Wenqi Fu; Yanhua Hao; Yu Cui; Weidong Huang; Peter C Coyte
Journal:  BMJ Open       Date:  2014-12-22       Impact factor: 2.692

10.  Impact of China's Public Hospital Reform on Healthcare Expenditures and Utilization: A Case Study in ZJ Province.

Authors:  Hao Zhang; Huimei Hu; Christina Wu; Hai Yu; Hengjin Dong
Journal:  PLoS One       Date:  2015-11-20       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.